• Search
  • Helpdesk
  • Sales contact

Tackling the specificities of NASH/MASH clinical trials

Last updated: May 7, 2025

Integrating PROs into studies on MASH, also known as NASH, is crucial. 
MASH is a debilitating chronic illness that significantly impairs patients’ quality of life, affecting their daily routines, work, and mobility.

  • Patient-centric appraisals are needed in the quest for treatments
  • Integrating PROs in MASH studies expands insights beyond MASH metrics, and helps understand MASH patients’ concerns


At Kayentis, we have the full capability to run your MASH studies successfully:

  • We have extensive experience in MASH and hepatic disorders research
  • We offer an enhanced patient-centric eCOA data entry
  • We are a key partner to biotech and big pharma companies
 
Download the case study 👇
Follow us on social media
Subscribe to our newsletter
About the author
Meet us at the following events

SCOPE Europe 2025

OCT 14-15 2025 • Barcelona, Spain
SCOPE Europe | Summit for Clinical Operations Executives | October 14-15, 2025 |Barcelona, Spain

Rethinking Phase 1 Oncology Trials with Electronic Patient-Reported Outcomes

November 4 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET
The primary aim of Phase 1 oncology clinical trials is to determine the safety of a new treatment, and to...